Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Clinical trial NCT04100694 · APPROVED_FOR_MARKETING

Trial details

NCT number: NCT04100694
Sponsor: Merus B.V.
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS

NRG1 Fusion Pancreatic Cancer Non Small Cell Lung Cancer Solid Tumor, Unspecified, Adult Prostate Cancer Head and Neck Cancer Colorectal Cancer Breast Cancer Cholangiocarcinoma Renal Cell Carcinoma Unknown Primary Tumors

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.